单克隆抗体在抗病毒感染中的研究进展  

Research Progress of Monoclonal Antibody in Viral Infection

作　　者：卜桐 崔乐乐 刘兆基 张涵旭 史雨 李爱梅[1] 考文萍[1] 翟爱霞[1] BU Tong;CUI Le-le;LIU Zhao-ji;ZHANG Han-xu;SHI Yu;LIAi-mei;KAO Wen-ping;ZHAI Ai-xia(Department of Microbiology,Harbin Medical University,Wu Lien-Teh institute,Heilongjiang Provincial Key Laboratory of Infection and Immunity,Key Laboratory of Pathogen Biology in Heilongjiang Provincial Education Institute,Science and Technology Innovation Team for Infection and Immunity in Heilongjiang Provincial Education Institute,Harbin,Heilongjiang,150081,China)

机构地区：[1]哈尔滨医科大学微生物学教研室伍连德研究所黑龙江省感染与免疫重点实验室黑龙江省普通高校病原生物学重点实验室黑龙江省普通高校感染与免疫科技创新团队,黑龙江哈尔滨150081

出　　处：《现代生物医学进展》2019年第6期1188-1192,共5页Progress in Modern Biomedicine

基　　金：国家自然科学基金项目(81501737);黑龙江省自然科学基金项目(H2015009);黑龙江省教育厅科学技术研究项目(12541365);黑龙江省博士后科研启动基金项目(LBH-Q14120)

摘　　要：单克隆抗体(monoclonal antibody, m Ab),指同一种抗原决定簇的细胞克隆所产生的均一性抗体。m Ab已成功应用以诊疗各种疾病,尤其是癌症和免疫性疾病。近些年来,m Ab逐渐用于治疗病毒性疾病,针对急性和慢性病毒感染研发的抗病毒m Ab数量逐渐增长。m Ab的组合疗法可同时靶向病毒多个表位,从而克服病毒免疫逃逸的问题,多价m Ab的设计开发能够更加有效的作用于病毒。本文比较了不同m Ab制备方法的优缺点,总结了m Ab近期在抗病毒感染领域的研究进展,并讨论了m Ab作为治疗病毒性疾病药物的前景。Monoclonal antibody refers to the homogenous antibody produced by the cell clone of the same antigen determinant.MAb has been successfully used in the treatment of various diseases,especially cancer and immune diseases.However,in recent years,monoclonal antibody has gradually been used to treat viral infections.The number of anti-viral monoclonal antibody developed for acute and chronic viruses has gradually increased.The combination therapy of m Ab can target multiple epitopes of virus at the same time,so as to overcome the problem of virus immune escape.The design and development of multivalent monoclonal antibody can act on virus more effectively.In this paper,the advantages and disadvantages of different preparation methods of m Ab were compared,and the recent research progress of m Ab in the field of antiviral was summarized.The prospect of m Ab as a drug for treating viral diseases was discussed.

关 键 词：单克隆抗体 抗病毒 作用机制 

分 类 号：Q78[生物学—分子生物学] R392.12[医药卫生—免疫学]